Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Paesmans

Showing results (111-120 of 187) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working PartyM Paesmans, J P Sculier, P Libert, et al.
The European Respiratory Journal|November 22, 2001
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysisE Steels, M Paesmans, T Berghmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patientsJ Klastersky, M Paesmans, E B Rubenstein, et al.
Lung Cancer (Amsterdam, Netherlands)|July 12, 2005
A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesotheliomaT Berghmans, J J Lafitte, M Paesmans, et al.
Scientific Reports|March 3, 2016
The current use and attitudes towards tumor genome sequencing in breast cancerI Gingras, A Sonnenblick, E de Azambuja, et al.
Revue Des Maladies Respiratoires|January 1, 1994
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party]J P Sculier, M Paesmans, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sitesD Gancberg, A Di Leo, F Cardoso, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 21, 2002
Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysisT Berghmans, M Paesmans, J J Lafitte, et al.
Revue Medicale De Bruxelles|January 29, 2002
[The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers]J P Sculier, T Berghmans, M Paesmans, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapyJ P Sculier, T Berghmans, J J Lafitte, et al.
Pageof 19

Showing results (111-120 of 187) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working PartyM Paesmans, J P Sculier, P Libert, et al.
The European Respiratory Journal|November 22, 2001
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysisE Steels, M Paesmans, T Berghmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patientsJ Klastersky, M Paesmans, E B Rubenstein, et al.
Lung Cancer (Amsterdam, Netherlands)|July 12, 2005
A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesotheliomaT Berghmans, J J Lafitte, M Paesmans, et al.
Scientific Reports|March 3, 2016
The current use and attitudes towards tumor genome sequencing in breast cancerI Gingras, A Sonnenblick, E de Azambuja, et al.
Revue Des Maladies Respiratoires|January 1, 1994
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party]J P Sculier, M Paesmans, G Bureau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sitesD Gancberg, A Di Leo, F Cardoso, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 21, 2002
Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysisT Berghmans, M Paesmans, J J Lafitte, et al.
Revue Medicale De Bruxelles|January 29, 2002
[The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers]J P Sculier, T Berghmans, M Paesmans, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2002
A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapyJ P Sculier, T Berghmans, J J Lafitte, et al.
Pageof 19